References
- McKelvey E. M., Gottlieb J. A., Wilson H. E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–93
- Praga C., Trave F., Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. Clinical Measurement in Drug Evaluation, W. S. Nimmo, et al. WOLFE Publishing Ltd., London 1991; 131–42
- Klimo P., Connors J. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals of Internal Medicine 1985; 102: 596–602
- Fisher R. I., De Vita V. T., Hubbard S. M., et al. Randomized trial of ProMACE-MOPP vs ProMACE-Cyta-BOM in previously untreated, advanced diffuse aggressive lymphomas. Proceedings of the American Society of Clinical Oncology. 1984; 3242
- Federico M., Moretti G., Gobbi P. G., et al. Pro-MACE-CytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial. Leukemia S 1991, Suppl 1: 95–101
- Case B. C., Hayes D. M., Gerber M., et al. Phase II study of oral idarubicin in favourable histology non-Hodgkin's lymphoma. Cancer Research 1990; 50: 6833–5
- Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 1984; 2: 1281–88
- Nie H. H., Hadlai Hull C., Jenkins J. G., et al. SPSS (Statistical Package for the Social Sciences). McGraw-Hill, New York 1979
- Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. I. Introduction and design. British Journal of Cancer 1976; M34: 585–612
- Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. II. Analysis and examples. British Journal of Cancer 1976; 35: 1–39